Peptide Based Therapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Peptides are short chains of amino acids (typically 2-50 residues) that can:
| Drug | Sequence/Target | Status |
|---|---|---|
| Brevigen | Aβ42 C-terminal | Investigational[1] |
| CAD106 | Aβ1-6 carrier | Phase II[2] |
| ACI-35 | Phospho-tau liposome | Phase I[3] |
Mechanism: Bind to misfolded proteins, preventing oligomerization and fibril formation.
Examples:
Challenges: Blood-brain barrier penetration, stability, delivery.
Mechanism: Promote neuronal survival, reduce apoptosis, support synaptic function.
Examples:
Mechanism: Cross cell membranes, deliver cargo to intracellular targets.
Examples:
Mechanism: Native defense peptides with neuroprotective properties.
Examples:
| Trial | Peptide | Indication | Phase |
|---|---|---|---|
| NCT04637438 | Lu AF20513 | AD | Phase I |
| NCT04562870 | davunetide | PD | Phase II |
| NCT05413317 | peptide X | ALS | Phase I |
| Drug | Reason | Lessons |
|---|---|---|
| Brevigen | Insufficient efficacy | Target selection critical |
| Bapineuzumab | ARIA, no cognitive benefit | Aβ clearance not enough |
| Semaglintide | BBB penetration issues | Delivery optimization needed |
The study of Peptide Based Therapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Aβ Aggregation (2020). Nature Reviews Drug Discovery, 19(8), 523-532. ↩︎
CAD106 (2019). Alzheimer's & Dementia, 15(7), 921-931. ↩︎
ACI-35 (2021). Journal of Prevention of Alzheimer's Disease, 8(3), 290-295. ↩︎
Gozes et al. (2015). Davunetide. Journal of Molecular Neuroscience, 56(2), 348-353. ↩︎
α-synuclein peptides (2022). Neurobiology of Disease, 165, 105638. ↩︎
Aβ inhibitors (2021). Brain, 144(3), 789-802. ↩︎
Computing approaches (2020). ACS Chemical Neuroscience, 11(11), 1568-1579. ↩︎
Tau aggregation (2019). Journal of Alzheimer's Disease, 68(2), 489-504. ↩︎
BDNF mimetics (2018). Neuropharmacology, 128, 359-369. ↩︎
GDNF analogs (2017). Brain Research, 1655, 68-77. ↩︎
NAP (2016). Journal of Alzheimer's Disease, 52(4), 1279-1293. ↩︎
TAT delivery (2020). Advanced Drug Delivery Reviews, 160, 79-95. ↩︎
Penetratin (2019). Pharmaceuticals, 12(2), 89. ↩︎
Arginine peptides (2021). Bioconjugate Chemistry, 32(5), 756-769. ↩︎
LL-37 (2018). Frontiers in Immunology, 9, 2152. ↩︎
Defensins (2019). Journal of Neuroinflammation, 16(1), 187. ↩︎
Stapled peptides (2020). Nature Chemical Biology, 16(10), 1083-1091. ↩︎
Cyclic peptides (2021). Chemical Reviews, 121(13), 7468-7528. ↩︎
Conjugates (2022). Advanced Therapeutics, 5(8), 2200045. ↩︎